0001654954-18-004258.txt : 20180423 0001654954-18-004258.hdr.sgml : 20180423 20180423160519 ACCESSION NUMBER: 0001654954-18-004258 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180419 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20180423 DATE AS OF CHANGE: 20180423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ChromaDex Corp. CENTRAL INDEX KEY: 0001386570 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 262940963 STATE OF INCORPORATION: DE FISCAL YEAR END: 1229 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37752 FILM NUMBER: 18768956 BUSINESS ADDRESS: STREET 1: 10005 MUIRLANDS BLVD. STREET 2: STE. G, FIRST FLOOR CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-419-0288 MAIL ADDRESS: STREET 1: 10005 MUIRLANDS BLVD. STREET 2: STE. G, FIRST FLOOR CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: CODY RESOURCES, INC. DATE OF NAME CHANGE: 20070112 8-K 1 cdxc8k.htm CURRENT REPORT Blueprint
 

 
UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
____________
 
FORM 8-K
 
CURRENT REPORT
 
     PURSUANT TO SECTION 13 OR 15(d) OF THE
 
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): April 19, 2018
 
CHROMADEX CORPORATION
 (Exact name of registrant as specified in its charter)
 
Delaware
001-37752
26-2940963
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
10005 Muirlands Boulevard, Suite G, Irvine, California, 92618
(Address of principal executive offices, including zip code)
 
(949) 419-0288
 (Registrant's telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
[  ]Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
[  ]Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
[  ]Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
[  ]Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
 

 
 
 
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On April 19, 2018, the Board of Directors (the “Board”) of ChromaDex Corporation (“ChromaDex”) unanimously approved a future transition of Frank L. Jaksch whereby Mr. Jaksch will transition from his role as ChromaDex’s Chief Executive Officer and principal executive officer, effective as of the conclusion of ChromaDex’s 2018 Annual Meeting of Stockholders expected to be held on June 22, 2018 (the “2018 Annual Meeting”), and instead serve as ChromaDex’s Executive Chairman, contingent and effective upon Mr. Jaksch’s re-election at the 2018 Annual Meeting. As Executive Chairman, Mr. Jaksch will serve as Chairman of the Board and will continue to serve as an employee and executive officer of ChromaDex. Mr. Jaksch’s Amended and Restated Employment Agreement, dated April 19, 2010, shall continue to govern the terms of Mr. Jaksch’s employment, subject to any future changes as approved by the Board or the Compensation Committee of the Board (the “Compensation Committee”).
 
Also on April 19, 2018, the Board appointed Kurt Gustafson as lead independent director of the Board, contingent and effective upon Mr. Gustafson’s re-election at the 2018 Annual Meeting.
 
Also on April 19, 2018, the Board unanimously approved a future transition of Robert Fried whereby Mr. Fried will transition from his role as ChromaDex’s President and Chief Operating Officer and instead serve as ChromaDex’s Chief Executive Officer and principal executive officer, each effective as of the conclusion of the 2018 Annual Meeting.
 
Mr. Fried, age 58, has served as a director of ChromaDex since July 2015 and served as a member of the Nominating and Corporate Governance Committee of the Board from July 2015 to March 2017. Mr. Fried was appointed President and Chief Strategy Officer of ChromaDex in March 2017 (which Chief Strategy Officer title he held until March 2018) and also became its Chief Operating Officer in January 2018. Mr. Fried served as Chairman of the Board of Directors of IDI, Inc. (formerly Tiger Media, Inc.), an information solutions provider focused on the data fusion market and formerly a Chinese advertising company prior to its merger with the parent company of Interactive Data, LLC, from 2011 until June 2015. From 2007 through 2009, he was the president, Chief Executive Officer and a director of Ideation Acquisition Corporation, a special purpose acquisition company. Mr. Fried is the founder and Chief Executive Officer of Feeln, a subscription streaming video service, which was acquired by Hallmark Cards Inc. in 2012. Since then, Mr. Fried manages digital businesses for Hallmark including Feeln, Hallmark e-cards, and Hallmark Print on Demand. Mr. Fried is also an Academy Award winning motion picture producer whose credits include Rudy, Collateral, Boondock Saints, So I Married an Axe Murderer, Godzilla, and numerous others. From December 1994 until June 1996, he was President and Chief Executive Officer of Savoy Pictures, a unit of Savoy Pictures Entertainment, Inc., which was sold in 1996 to Silver King Communications, which is now a part of InterActive Corp. Mr. Fried has also held several executive positions including Executive Vice President in charge of Production for Columbia Pictures, Director of Film Finance and Special Projects for Columbia Pictures, and Director of Business Development at Twentieth Century Fox. Mr. Fried holds an M.S. from Cornell University and an M.B.A. from the Columbia University Graduate School of Business.
 
As previously disclosed, Mr. Fried is a party to an Executive Employment Agreement, dated March 12, 2017, as amended on December 20, 2017 (the “Fried Employment Agreement”), and ChromaDex’s standard indemnification agreement for directors and executive officers. The Fried Employment Agreement shall continue to govern the terms of Mr. Fried’s employment, subject to any future changes as approved by the Board or the Compensation Committee. Also as previously disclosed, on March 12, 2017, ChromaDex acquired all of the outstanding equity interests of Healthspan Research, LLC (“Healthspan”) pursuant to a Membership Interest Purchase Agreement (the “Purchase Agreement”) by and among (i) Mr. Fried, Jeffrey Allen and Dr. Charles Brenner (the “Sellers”) and (ii) ChromaDex (the “Acquisition”). Pursuant to the Purchase Agreement, ChromaDex purchased all of the outstanding membership interests from the Sellers. Upon the closing of, and as consideration for, the Acquisition, ChromaDex issued an aggregate of 367,648 unregistered shares of ChromaDex’s common stock to the Sellers, including 339,595 shares of ChromaDex’s common stock issued to Mr. Fried, and, in cancellation of a loan owed by Healthspan to Mr. Fried, paid $32,500 and $100,000 to Mr. Fried on March 12, 2017 and March 9, 2018, respectively.
 
There are no arrangements or understandings between Mr. Fried and any other persons pursuant to which he was selected as ChromaDex’s Chief Executive Officer and there are also no family relationships between Mr. Fried and any of ChromaDex’s directors or executive officers.
 
On April 23, 2018, ChromaDex issued a press release announcing the future transitions of Mr. Jaksch from Chief Executive Officer to Executive Chairman and Mr. Fried from President and Chief Operating Officer to Chief Executive Officer. A copy of the press release is attached as Exhibit 99.1 hereto.
 
Item 9.01 Financial Statements and Exhibits.
 
 (d) Exhibits.
 
ExhibitNumber
 
Description
 
 
 
Press Release dated April 23, 2018.
 
 
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
CHROMADEX CORPORATION
 
 
 
Dated: April 23, 2018
 
 
 
 
 
 
 
 
 
 
 
 
By:
 
/s/ Kevin Farr
 
 
 
 
 
 
Name: Kevin Farr
 
 
 
 
 
 
Chief Financial Officer
 
 
 
 
 
 
 
EX-99.1 2 ex99-1.htm PRESS RELEASE Blueprint
 
Exhibit 99.1
 
ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director
 
New Management Structure Further Fuels Strategic Evolution into Consumer-Focused Integrated Nutraceutical Company
 
IRVINE, Calif., April 23, 2018 (GLOBE NEWSWIRE) –ChromaDex Corp. (NASDAQ: CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, today announced a new management structure including the appointment of Frank Jaksch to Executive Chairman of the ChromaDex Board of Directors, effective June 22, 2018 after the 2018 Annual Meeting of Stockholders.
 
Mr. Jaksch succeeds Stephen Allen, the non-executive Chairman of the ChromaDex Board, who on February 13, 2018, announced his intention to retire at the end of his current term.
 
Mr. Jaksch is a co-founder of the Company, and has served as the CEO from 2000 to January 2012, and again as CEO since June 2012. Mr. Jaksch has also served as a member of the Board since February 2000. Mr. Jaksch will continue to be an active part of the executive management team on strategic and scientific advice and guidance, new product development and represent the Company in its relations with trade associations and others in the industry. “In just the last few years, we have seen an explosion in the amount of scientific research around NIAGEN® which is incredibly important to the consumers’ understanding of healthy aging and the role our TRU NIAGEN® product plays in that process,” said Frank Jaksch. “We have had a very successful transition to the TRU NIAGEN consumer product business and we are still in the early stages of this tremendous opportunity. I firmly believe this is the right time to make these changes, as the Company continues to increase its presence in the global market place .”
 
 
“We are thrilled that both the Board and the Company will continue to benefit from Frank’s immense scientific knowledge and decades of experience in the nutraceutical industry as he continues to work alongside the business, industry and science thought leaders on our Scientific Advisory Board,” said Steve Allen.
 
ChromaDex also announced that Rob Fried, the Company’s current President and Chief Operating Officer, has been named CEO of the company, effective after the June 22, 2018 Annual Meeting of Stockholders. Mr. Fried will succeed Frank Jaksch as CEO.
 
“Over the last year, under Rob’s leadership, ChromaDex has evolved from an ingredient company to a global, consumer brand organization focused on developing and marketing products and technologies that improve how people age,” said Steve Allen, “and the Board of Directors thanks Frank for his years of leadership and Frank’s commitment to collaborate with Rob during this period to ensure a smooth transition.”
 
“In 2017, we made progress in our organizational shift, bringing new and diversified expertise into the organization and launching TRU NIAGEN in the U.S. and Hong Kong. I look forward to continuing to work with the talented people at ChromaDex to build on our momentum and broaden the body of clinical research around NIAGEN. We will continue to focus on expanding our distribution into international markets, leveraging our robust intellectual property and deploying our strong balance sheet to deliver substantial global growth in sales of TRU NIAGEN,” said Rob Fried.
 
In addition, ChromaDex announced that the Board of Directors has appointed Kurt Gustafson, a director of ChromaDex since 2016, as Lead Independent Director, effective after the 2018 Annual Meeting of Stockholders. Mr. Gustafson will also continue to be the Chairman of the Audit Committee. “I look forward to working with Frank and the rest of the board to guide the Company towards its mission of healthy aging during this important phase of growth,” said Kurt Gustafson.
 
 
 
 
 
About ChromaDex:
 
ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
 
Forward-Looking Statements:
 
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the transitions of Mr. Jaksch as Executive Chairman, Mr. Fried as Chief Executive Officer and Mr. Gustafson as Lead Independent Director, whether ChromaDex will broaden the body of clinical research around NIAGEN® and whether ChromaDex will expand distribution into international markets and deliver substantial global growth in sales of TRU NIAGEN®. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 30, 2017, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. ChromaDex provided research materials and a portion of the grant funding as a collaborator for the study.
 
ChromaDex Media Contact:
Alex Worsham, Director of Strategic Partnerships
949-648-3775
alexw@chromadex.com
 
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations 
949-419-0288
andrewj@chromadex.com
END
###